ArticleDermatology practical & conceptual2026
Systemic Immune-Inflammation Index and Systemic Inflammation Response Index in Psoriasis: Limited Utility for Monitoring Response to IL-23 Inhibitors.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsoriasis is a chronic inflammatory skin disease frequently associated with systemic inflammation. Recently, blood cell-derived markers such as the Systemic Immune Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) have been proposed as potential biomarkers for disease activity and treatment monitoring. However, their clinical relevance in patients undergoing biological therapy, particularly IL-23 inhibitors, has not been fully explored.
objectivesTo evaluate the utility of SII and SIRI in monitoring disease activity in patients with severe psoriasis treated with guselkumab, risankizumab, or tildrakizumab.
methodsThis retrospective observational study included 120 patients with moderate-to-severe psoriasis treated with IL-23 inhibitors over 12 months. SII, SIRI, and Psoriasis Area and Severity Index (PASI) were assessed at baseline, six months, and 12 months. Correlations between inflammatory indices and some comorbidities were analyzed.
resultsDespite significant PASI improvement across all treatment groups, SII and SIRI values showed inconsistent fluctuations and did not parallel clinical response. While SII decreased slightly in the tildrakizumab group, no consistent trend was observed in guselkumab and risankizumab cohorts. SIRI demonstrated similarly variable behavior. Weak-to-moderate correlations were noted between inflammatory indices and comorbidities such as obesity, diabetes mellitus, and hypertension.
conclusionsSII and SIRI do not reliably reflect treatment response in psoriasis patients receiving IL-23 inhibitors. Their variability and correlation with comorbidities suggest limited value as psoriasis-specific biomarkers. More targeted indicators are needed for accurate monitoring of systemic inflammation in this setting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.